公开(公告)号：US20240197715A1

公开(公告)日：2024-06-20

申请号：US18510836

申请日：2023-11-16

Applicant: NOVARTIS AG

Inventor： Rita ANDRAOS-REY ,  Sandra BLUM-KALLERT ,  Marta CORTES-CROS ,  Ruben DE KANTER ,  Stephane FERRETTI ,  Isabel Cristina Colaco Farias JACO ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Laurent LABORDE ,  Henrik MOEBITZ ,  Michele MOSCHETTA ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG

IPC: A61K31/4745 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/243 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/243 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a subject in need thereof the WRN inhibitor in combination with the at least one additional therapeutically active agent. For example, the WRN inhibitor compound, or a pharmaceutically acceptable salt thereof, is of formula (I):




wherein R1, R2, R3, R4, R5, R28, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein.